

Suvaxyn Parvo-E Amphigen

Not authorised

- Porcine parvovirus, strain S-80, Inactivated
- Erysipelothrix rhusiopathiae, serotype 2, Inactivated

Product identification

Medicine name:

Suvaxyn Parvo-E Amphigen

Suvaxyn Parvo/E-Amphigen, süsteemulsioon sigadele

Active substance:

Porcine parvovirus, strain S-80, Inactivated

Erysipelothrix rhusiopathiae, serotype 2, Inactivated

Target species:

Pig

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Porcine parvovirus, strain S-80, Inactivated

94.10 haemagglutination inhibiting unit(s) / 2.00 millilitre(s)

Erysipelothrix rhusiopathiae, serotype 2, Inactivated

13.50 relative potency / 2.00 millilitre(s)

Pharmaceutical form:

Emulsion for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI09AL01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Surrendered

Authorised in:

Estonia

Package description:

box containing 1 vial of 50 ml (25 doses)

box containing 1 vial of 20 ml (10 doses)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Belgium

Marketing authorisation date:

6/12/2016

Manufacturing sites for batch release:

Zoetis Manufacturing & Research Spain S.L.

The Veterinary Medicines Directorate

Paul-Ehrlich-Institute

Responsible authority:

State Agency Of Medicines

Authorisation number:

2003

Date of authorisation status change:

29/01/2023

Reference member state:

Spain

Procedure number:

ES/V/0266/001

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.